Novogenia AG (ticker symbol: 7V0, formerly Darwin AG), an international healthcare company specializing in human genetics and personalized products, announced today the U.S. market launch of its new MGT Plus methylation test. The launch, conducted in collaboration with U.S. partner 10X Health, marks a significant expansion of their joint product pipeline and reinforces their commitment to advancing genetic analysis and longevity research.
Methylation is a fundamental biochemical process involved in numerous metabolic and regulatory functions in the human body. It plays a critical role in the processing of vitamins, neurotransmitters, and other biological molecules, influencing overall health and disease prevention. While standard commercial tests typically analyze only a limited set of genes, MGT Plus covers a total of 27 genes, offering a more comprehensive view of methylation processes across six interconnected biological pathways: energy and nutrient metabolism, stress and neurotransmitter regulation, and vascular, immune, and cellular health.
This expanded scope provides healthcare providers and individuals with deeper insights into genetic factors affecting methylation-related metabolic pathways. By identifying variations in these genes, MGT Plus enables more precise, personalized prevention and health strategies. Dr. Daniel Wallerstorfer, CEO of Novogenia AG, emphasized the significance of the test: "With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes. The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways in the body, creating new opportunities for more personalized prevention and health strategies." He added, "Our close collaboration with our U.S. partner 10X Health underscores our commitment to making scientific innovations accessible internationally and actively advancing personalized approaches to preventive health."
The launch comes at a time when the global direct-to-consumer testing market is experiencing robust growth. In 2025, the market was valued at approximately $4.7 billion and is projected to reach over $16.0 billion by 2033. Genetic testing represents the largest segment, accounting for over 40% of the market, with North America leading globally at about 50% of the market volume in 2025. This growth is driven by increasing consumer interest in personalized health information, prevention, and tailored health services.
For business and technology leaders, this development signals a growing opportunity in the personalized medicine and wellness sector. The MGT Plus test not only exemplifies innovation in genetic analysis but also highlights the commercial viability of advanced diagnostic tools. As the market expands, companies that offer comprehensive, actionable genetic insights are likely to gain a competitive edge. Furthermore, the collaboration between Novogenia and 10X Health demonstrates the value of strategic partnerships in bringing cutting-edge health technologies to a broader audience.
The implications for the healthcare industry are substantial. With more detailed methylation analysis, clinicians can better understand individual metabolic and regulatory processes, potentially leading to more effective interventions and preventive measures. This aligns with a broader trend toward precision medicine, where treatments and health recommendations are tailored to an individual's genetic makeup. For investors and industry observers, Novogenia's expansion into the U.S. market underscores the growing importance of genetic testing as a cornerstone of modern healthcare.
Novogenia AG, headquartered in Munich, Germany, operates its own laboratory for genetic analyses used in disease diagnosis, treatment, and prevention, as well as in the production of personalized nutritional supplements and cosmetics. The company partners with physicians, therapists, and fitness trainers to optimize patient care based on genetic predispositions. With this launch, Novogenia continues to solidify its position as a leader in the international genetic testing landscape.
